Adempas and Zolpidem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Adempas (riociguat) and Zolpidem (zolpidem tartrate). Common drug interactions include choking among females and nausea among males.

The phase IV clinical study analyzes what interactions people have when they take Adempas and Zolpidem. It is created by eHealthMe based on reports of 98 people who take the same drugs from the FDA, and is updated regularly.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.

What is Zolpidem?

Zolpidem has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 92,695 Zolpidem users. Check the latest studies of Zolpidem.



On Jul, 09, 2026

98 people who take Adempas and Zolpidem together, and have interactions are studied.

Adempas and Zolpidem drug interactions.

What are the common drug interactions of Adempas and Zolpidem, by gender? *:

female:

  1. Choking (mechanical obstruction of the flow of air from the environment into the lungs)
  2. Nasal congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels)
  3. Pulmonary arterial pressure decreased
  4. Adrenal insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids)
  5. Malaise (a feeling of general discomfort or uneasiness)
  6. Dehydration (dryness resulting from the removal of water)
  7. Flushing (the warm, red condition of human skin)
  8. Abdominal pain
  9. Cough
  10. Dizziness

male:

  1. Nausea (feeling of having an urge to vomit)
  2. Hypoxia (low oxygen in tissues)
  3. Erythema (redness of the skin)
  4. Pain in extremity
  5. Abdominal distension
  6. Diarrhoea
  7. Blood pressure decreased
  8. Hypotension (abnormally low blood pressure)
  9. Pain
  10. Cardiac disorder

What are the common drug interactions of Adempas and Zolpidem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Abdominal discomfort
  2. Acne (skin problems that cause pimples)
  3. Alanine aminotransferase increased
  4. Aspartate aminotransferase increased
  5. Blood potassium decreased
  6. Blood pressure decreased
  7. Blood thyroid stimulating hormone decreased
  8. Catheter site erythema (redness of skin at catheter site)
  9. Catheter site haematoma (blood clot at catheter site)
  10. Catheter site haemorrhage (bleeding at catheter site)

30-39:

  1. Alanine aminotransferase increased
  2. Anaemia (lack of blood)
  3. Capillary permeability increased (increased ability of small blood vessels to pass fluid in and out)
  4. Cardiac failure
  5. Device related infection
  6. Epistaxis (bleed from the nose)
  7. Prerenal failure
  8. Pulmonary hypertension (increase in blood pressure in the lung artery)
  9. Renal impairment (severely reduced kidney function)
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

40-49:

  1. Headache (pain in head)
  2. Pyrexia (fever)
  3. Diarrhoea
  4. Dyspnoea (difficult or laboured respiration)
  5. Malaise (a feeling of general discomfort or uneasiness)
  6. Nausea (feeling of having an urge to vomit)
  7. Dizziness
  8. Fatigue (feeling of tiredness)
  9. Flushing (the warm, red condition of human skin)
  10. Vomiting

50-59:

  1. Diarrhoea
  2. Flushing (the warm, red condition of human skin)
  3. Drug level decreased
  4. Erythema (redness of the skin)
  5. Headache (pain in head)
  6. Weight increased
  7. Dizziness
  8. Hypoxia (low oxygen in tissues)
  9. Abdominal distension
  10. Chest pain

60+:

  1. Nausea (feeling of having an urge to vomit)
  2. Hypoxia (low oxygen in tissues)
  3. Concomitant disease progression (progress in accompanying disease)
  4. Duodenal neoplasm (tumour of duodenal)
  5. Electrolyte imbalance
  6. Loss of consciousness
  7. Myelofibrosis (a disease in which abnormal blood cells and fibres build up inside the bone marrow)
  8. Pancreatitis (inflammation of pancreas)
  9. Platelet count decreased
  10. Pleural effusion (water on the lungs)

What are the existing conditions these people have? *

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 78 people, 79.59%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 20 people, 20.41%
  3. Right Ventricular Failure (right half of the heart fails to work): 7 people, 7.14%
  4. Pain: 6 people, 6.12%
  5. High Blood Pressure: 6 people, 6.12%
  6. Sleep Disorder: 5 people, 5.10%
  7. Diarrhea: 5 people, 5.10%
  8. Cardiac Failure: 5 people, 5.10%

* Approximation only. Some reports may have incomplete information.

Do you take Adempas and Zolpidem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Adempas and Zolpidem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Zolpidem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Adempas and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Zolpidem and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on riociguat and zolpidem tartrate (the active ingredients of Adempas and Zolpidem, respectively), and Adempas and Zolpidem (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: